Senior Scientist/Principal Scientist, Quantitative Pharmacology (Contractor)

Senior Scientist/Principal Scientist, Quantitative Pharmacology (Contractor) Employer Legend Biotech Location Somerset, New Jersey Start date Apr 24, 2026 categoriesView less categories Job Details Company Job Details Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking Senior Scientist/Principal Scientist, Quantitative Pharmacology (Contractor) as part of the Research & Early Development team based in Somerset, NJ. Role Overview The position seeks a highly motivated and experienced quantitative pharmacologist to lead modeling and simulation efforts in support of gene and cell therapy products, with a focus on QSP and popPK modeling (Prior cell and gene therapy experience preferred).

Contract Duration:

12 Months Key Responsibilities Lead QSP and popPK modeling activities across preclinical and clinical development stages. Play a pivotal role in shaping clinical pharmacology strategies, supporting regulatory submissions, and driving innovation in model-informed drug development (MIDD). Develop and apply mechanistic models to understand disease pathways, drug mechanisms, and patient variability. Conduct simulations to support dose selection, trial design, and exposure-response analyses. Collaborate cross-functionally with R D, clinical, regulatory, and biostatistics teams. Author and review clinical pharmacology sections of regulatory documents (e.g., INDs, NDAs). Contribute to scientific publications and conference presentations. Requirements R D, Preclinical development, Clinical, CMC and regulatory MS/PhD/Pharm D in Pharmaceutical Sciences, Clinical Pharmacology, Applied Mathematics, Biomedical Engineering, or related quantitative discipline. 7+ years with MS degree or 3+ years with PhD/Pharm D degree of working experience in quantitative pharmacology or pharmacometrics in pharmaceutical companies or CRO companies (Job titles will be decided per applicant's working experience) Have strong execution ability Strong independent scientific research ability, logical thinking, and coordination/problem-solving skills Have clear written and oral communication skills Have a good team spirit Demonstrated expertise in QSP and popPK modeling, including proficiency with tools such as NONMEM, R, MATLAB, Monolix, etc. Deep understanding of PK/PD principles, translational medicine, and the role of quantitative pharmacology and model-informed drug development (MIDD) in clinical trials and drug development. Demonstrated ability and experience in applying modelling and simulation approaches to enable rational and efficient preclinical and clinical drug development. Familiar with regulatory requirements and guidelines of clinical pharmacology. Good project management skills, and the ability to collaborate with other departments and manage with internal and external partners. Proven track record of scientific contributions through publications or presentations. Good personality, honest and trustworthy. Physically and mentally healthy, love life. #Li-JR1 #Li-Contractor #Li-Hybrid Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech. EEO Statement It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances. Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company. For information related to our privacy notice, please review: Legend Biotech Privacy Notice. Company Legend Biotech was founded as an early-stage cell therapy company in 2014. The company was the brainchild of visionary scientists who recognized that antibody-based therapeutics could potentially treat disease and possessed the backgrounds in immunology and gene editing to take the leap. For two years, Legend Biotech, then known as the "Legend Project," operated in a room the size of a freight elevator, with the goal of creating a cell therapy for multiple myeloma, a hematological cancer that often relapses and can become refractory. The team produced nanobodies for single-domain antibody drugs and ultimately extended the half-life of the nanobodies with proprietary technologies. In 2015, Legend's scientists focused on research for chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein, making the biotech one of the first companies in the world to engineer CAR-T cells for the BCMA protein. In 2016, investigator-initiated trials began in China. In 2017, data from the trials were presented at the American Society for Clinical Oncology (ASCO), which led to a partnership with biopharmaceutical company Janssen Biotech, Inc. to co-develop the anti-BCMA CAR-T, ciltacabtagene autoleucel (cilta-cel). Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world.

CARVYKTI

™ (ciltacabtagene autoleucel) was approved by the U.S. Food and Drug Administration in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022. Today Legend Biotech is a global, commercial-stage company driven by a passion for patients. We continue to build our pipeline of cell therapy platforms, which includes CAR-T, CAR-NK, CAR-γδ T and non-gene-editing CAR technologies. Our goal is to bring hope and opportunity to patients and their families by continuing to explore unique technologies. Company info Location Somerset New Jersey United States